FDA Extends Review of BLA for Orca-T in Hematologic Malignancies | OncLive The FDA has extended the PDUFA date for the Orca-T BLA to July 6, 2026.

Following the submission of updated CMC information, the FDA has extended the review period of the BLA seeking the approval of Orca-T for the treatment of select patients with hematologic malignancies.

Read more on the new regulatory timeline #leusm #lymsm #oncology www.onclive.com/view/fda-ext...

Ultrasensitive ctDNA-MRD Validated Following First-Line Therapy in LBCL Researchers determined detecting ctDNA-MRD with the PhasEd-Seq is a valid approach in LBCL and warrants further integration of MRD into assessments involving clinical responses.

Ultrasensitive ctDNA assays for #MRD detection show 100% specificity in predicting LBCL relapse. Phased variants outperform trackable mutations for early identification of treatment failure. From @ascopost.bsky.social.

Read the review: https://bit.ly/4t6hoEj

#lymsm #MedEd #LBCL

Researchers Develop Externally Validated Prognostic Model for Newly Diagnosed Follicular Lymphoma Researchers determined the FLIPI24 prognostic model performs excellently in cases of newly diagnosed follicular lymphoma.

The FLIPI24 prognostic model performs excellently in cases of newly diagnosed #follicularLymphoma, demonstrating superiority over existing models. Published in @ascopost.bsky.social.

https://bit.ly/4uTbTuo

#lymsm

As the Global Burden of Hodgkin Lymphoma Decreases, Disparities Persist Incidence of Hodgkin lymphoma has decreased globally and is projected to continue to decrease through 2035, but lower SDI regions demonstrated more modest decreases in HL incidence and mortality.

Analysis of #HodgkinLymphoma burden from 1990–2019 reveals a 31.2% increase in global cases. Significant disparities persist in mortality rates and access to care across varying sociodemographic regions.

Read the review: ➡️ https://bit.ly/4uMFfui

#lymsm #globalhealth #lymphoma

BREAKING 🚨: @fda.gov Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma

Read more about this decision below 📰⬇️ www.onclive.com/view/fda-app...

#lymsm #oncology #FDAapproved

SWOG SOO16: CHOP-Based Chemoimmunotherapy Achieves Cure in Certain Advanced-Stage Follicular Lymphoma Patients Investigators analyzed OS and PFS for patients with follicular lymphoma following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/ prednisolone (CHOP)–based regimens at 15 years.

After 15 years of follow-up, a “substantial subset” of patients with previously untreated advanced #follicularLymphoma achieved cure with CHOP-based chemoimmunotherapy. Published in @jamaoncology.com and @cancertherapyadv.bsky.social.

https://bit.ly/46TSlM0

#lymsm

Acalabrutinib-Based Triplets Yield uMRD CRs in Previously Untreated Mantle Cell Lymphoma | OncLive Acalabrutinib/lenalidomide in combination with rituximab or obinutuzumab generated uMRD6 CRs in previously untreated mantle cell lymphoma.

Building on findings from a prior phase 2 trial, the addition of rituximab or obinutuzumab to the combination of acalabrutinib and lenalidomide led to CRs with uMRD in newly diagnosed MCL.

Read more on these phase 2 data @weillcornell.bsky.social #lymsm #oncology www.onclive.com/view/acalabr...

Pirtobrutinib Safe and Effective in Relapsed/Refractory Follicular Lymphoma Researchers determined pirtobrutinib was effective and well-tolerated among a cohort of patients with heavily pretreated relapsed/refractory follicular lymphoma.

Pirtobrutinib was effective and well-tolerated among a cohort of patients with heavily pretreated R/R #follicularLymphoma. Published in @bloodjournals.hematology.org.

https://bit.ly/4lnz63e

#lymsm

New anatomic classification R/R SCNSL
- 162 pts, 42 with both CNS+systemic dx
- leptomeningeal dx = inferior OS in MV model
- 4 subtypes w/ distinct PFS & OS: parenchymal +/- systemic and LM +/- systemic (see KM curve)
Useful schema in future trials. #lymsm
onlinelibrary.wiley.com/doi/10.1002/...

Glofitamab CNS penetration @bloodadvances.bsky.social
- 8 PCNSL/SCNSL, 7 LBCL, 1 BL
- 3/8 CRS (all G1-2), no ICANS
- 7/8 response (4 CR, 3 PR)
- 2 PCNSL durable CRs
- CSF: +glofi with activity in vitro
Bridging to CAR for SCNSL or even monotx for PCNSL. #lymsm
ashpublications.org/bloodadvance...

Tazemetostat pulled from the market this morning due to secondary malignancy risks seen in the SYMPHONY-1 trial. #lymsm

Venetoclax-Obinutuzumab Yields Comparable Efficacy in Fit and Unfit Patients With CLL - Oncology Nurse Advisor Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.

Venetoclax–obinutuzumab demonstrated comparable efficacy and tolerability in both fit and unfit patients with previously untreated chronic #lymphocyticLeukemia. Published in @bloodjournals.hematology.org and @hematologyadvisor.bsky.social.

https://bit.ly/4cvVQvQ

#lymsm #leusm #CLL

HRQoL Complements Clinician Reports in Assessing the Use of Pola-R-CHP in Previously Untreated DLBCL Researchers determined HRQoL can play a complementary role to clinician-reported AEs to more fully represent the efficacy and tolerability of Pola-R-CHP in DLBCL.

Clinical Snapshot: #DLBCL QoL Reporting 📊

• Data: Clinicians underreport symptoms vs patients (Kappa 0.16–0.44).
• Impact: Leads to inaccurate risk assessments.

From @bloodjournals.hematology.org. Read: https://bit.ly/4u2XCuL

#HemeOnc #lymsm

BREAKING: FDA Approves First-Line Acalabrutinib Plus Venetoclax for CLL/SLL @fda.gov @danafarber.bsky.social @harvardmed.bsky.social #lymsm #leusm #hematology
www.onclive.com/view/fda-app...

Medicare Advantage for People with Blood Cancers: Friend or Foe? | Podcast | ASCO Publications Dr. Chino welcomes Hari Raman, MD, MBA, author of “End-of-Life Care for Older Adults With Blood Cancers With Medicare Advantage Versus Medicare Fee-For-Service Insurance,” to discuss new research high...

Capacity for receiving appropriate #leusm #lymsm specialty cancer care is a known concern with #MedicareAdvantage plans, but paradoxically, there may be unique advantages for those at the end of life. 

🎙️I spoke to Dr Hari Raman from @danafarber.bsky.social for a new @ascocancer.bsky.social podcast

We found ORR 70 (CR 45%) of bispecifics after CAR-T, with mPFS 8.9 mos and median DOR and OS not reached. Patients with late post-CAR relapse (>6 months) who were treated with CD20 bispecifics had better outcomes. Infections were common, highlighting cumulative immunosuppression. #lymsm

Real-World Analysis Sheds Light on Bispecific Antibody Activity After CAR T in Mantle Cell Lymphoma | OncLive Real-world data suggest CD20 bispecific antibodies show activity after CD19 CAR T in mantle cell lymphoma, though durability of response remains unclear.

Many thanks to @onclive.bsky.social for reviewing our #Tandem26 abstract on outcomes of CD20 bispecifics after CD19 CAR in R/R MCL, an analysis from the CUBIC Consortium. #lymsm #tcellrx
Abstract link: www.astctjournal.org/article/S266...
www.onclive.com/view/real-wo...

The authors of this Blood Cancer Discovery study conducted a comparative analysis of the long-term efficacy and safety of two single-arm trials for relapsed/refractory diffuse large B-cell #lymphoma.

👉Read more: Long-term Outcomes of CAR T ± ASCT in R/R DLBCL buff.ly/m8e6taD #lymsm #cartcell

Yescarta Limitations of Use Removed for Primary CNS Lymphoma Based on phase 1 safety data, the FDA has removed the Limitations of Use for Yescarta in patients with relapsed or refractory primary CNS lymphoma.

The @fda.gov has approved updated labeling for Yescarta® (axicabtagene ciloleucel), removing the Limitations of Use statement for patients with R/R primary central nervous system #lymphoma. From @medicalprofref.bsky.social.

https://bit.ly/3MtH6D1

#lymsm

Real-Word Population Further Validates CAR-HEMATOTOX for CAR-T Therapy Utilizing the CAR-HEMATOTOX score among patients with R/R LBCL was reaffirmed in a larger, real-world cohort with respect to neutropenia.

Risk stratification for risk of neutropenia, infections, and survival outcomes using CAR-HEMATOTOX score among patients with R/R LBCL receiving CAR T-cell therapy was reaffirmed in a larger, real-world cohort. Published in @bloodjournals.hematology.org.

https://bit.ly/4cmEMbk

#lymsm #lymphoma

Long-Term Ibrutinib Plus Venetoclax Data Demonstrate Durable, Strong Responses in R/R MCL | OncLive Ibrutinib plus venetoclax yielded sustained complete response rates and a favorable safety profile in relapsed/refractory mantle cell lymphoma.

Long-Term Ibrutinib Plus Venetoclax Data Demonstrate Durable, Strong Responses in R/R MCL #lymsm #hematology #oncology
www.onclive.com/view/long-te...

What is an overused oncology buzzword❓Experts at #Tandem26 weighed in with their own hot takes. 🤔

@astct.bsky.social @cibmtr.bsky.social #lymsm #leusm #melsm #oncology #hematology #AI

Check out the video here ➡️: www.onclive.com/shorts/overu...

WATCH: Peter Riedell, MD, discusses the long-term efficacy of tisagenlecleucel in the third-line setting in patients with relapsed/refractory follicular lymphoma. @astct.bsky.social @cibmtr.bsky.social #Tandem26 #lymsm #hematology
www.onclive.com/view/dr-ried...

What do you bring with you to every conference❓

Check out how experts at #Tandem26 answered. 😂

@astct.bsky.social @cibmtr.bsky.social #mmsm #lymsm #leusm #oncology
#hematology

Watch the whole video here ➡️: www.onclive.com/shorts/hemat...

Axi-cel can now be used for R/R PCNSL! HT @samyamshon.bsky.social #lymsm #tcellrx

The @fda.gov has approved an update to the prescribing information for axi-cel, removing prior Limitations of Use for patients with relapsed/refractory primary central nervous system lymphoma #lymsm #oncology www.onclive.com/view/fda-upd...

New publication 📝 BRUIN CLL-314 phase III results, published in the Journal of Clinical Oncology, show that pirtobrutinib demonstrated noninferior ORR to ibrutinib (87.0% vs 78.5%; p < 0.0035) in TN or R/R BTKi-naïve CLL/SLL.

Learn more: https://loom.ly/jLklx8s

#leusm #lymsm #MedNews #MedEd

Thank you to Dr Nathan Denlinger, of @osucccjames.bsky.social, for stopping by during #Tandem26 to talk about real-world data with CAR T-cell therapy in LBCL!
See our site for more from the meeting! @astct.bsky.social @cibmtr.bsky.social #lymsm #hematology
www.onclive.com/conference/tct

Infx post CD20 bispecifics @bloodadvances.bsky.social
- 122 pts
- 61% ≥1 infx episode; 37% had Grade 3+ infx!!! (lots of CMV)
- 76% cumulative incidence infx at 2 yrs
- 8% G5 infx at 1 year
Important data (more infx than CAR?); need ppx/IVIG strategies. #lymsm
ashpublications.org/bloodadvance...

New publication📝 5-year follow-up results from the phase II JULIET trial, published in the Journal of Clinical Oncology, show tisagenlecleucel had an ORR of 53.0% in patients with R/R LBCL, with the median DoR not reached.

Learn more: https://loom.ly/rC-uX7Y

#lymphoma #lymsm #MedNews #MedEd